Inventor · disambiguated record
Marina Bacac
Also filed as: BACAC MARINA
24 granted patents·42 pending applications·183 citations·filing 2011–2025
96Inventor score
Top patents by PatentIndex Score
66 records- 0197US10577429B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2015·Granted Mar 3, 2020·17 cites·28 claims
- 0297US10253110B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2015·Granted Apr 9, 2019·15 cites·17 claims
- 0396US11718680B2Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonistsHOFFMANN LA ROCHE·Filed 2020·Granted Aug 8, 2023·5 cites·32 claims
- 0494US11332545B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2019·Granted May 17, 2022·6 cites·9 claims
- 0594US10683369B2Monoclonal antibodies against BCMAENGMAB SARL·Filed 2016·Granted Jun 16, 2020·14 cites·21 claims
- 0694US9914776B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2015·Granted Mar 13, 2018·16 cites·42 claims
- 0794US9011847B2Anti-FAP antibodies and methods of useBACAC MARINA·Filed 2011·Granted Apr 21, 2015·34 cites·26 claims
- 0893US10781258B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Granted Sep 22, 2020·4 cites·39 claims
- 0993US10155815B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2014·Granted Dec 18, 2018·12 cites·46 claims
- 1092US11117965B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Granted Sep 14, 2021·2 cites·35 claims
- 1192US10611841B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·41 claims
- 1292US10611840B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2018·Granted Apr 7, 2020·4 cites·5 claims
- 1392US9963513B2Method for the selection of antibodies against BCMAENGMAB AG·Filed 2014·Granted May 8, 2018·19 cites·5 claims
- 1491US11459404B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2017·Granted Oct 4, 2022·5 cites·1 claims
- 1587US10253104B2Bispecific antibodies against CD3ϵ and BCMAENGMAB AG·Filed 2015·Granted Apr 9, 2019·10 cites·16 claims
- 1687US2024141044A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1785US10781257B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Granted Sep 22, 2020·1 cites·34 claims
- 1884US10077315B2Bispecific antibodies against CD3 and BCMAENGMAB AG·Filed 2014·Granted Sep 18, 2018·6 cites·5 claims
- 1984US2023287118A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2083US12286486B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2022·Granted Apr 29, 2025·0 cites·17 claims
- 2183US2023076791A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2022·Application pending·0 cites
- 2282US2022403027A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 2381US10596257B2Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodiesHOFFMANN LA ROCHE·Filed 2017·Granted Mar 24, 2020·5 cites·52 claims
- 2481US2022064296A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 2580US10851171B2Method for the selection of antibodies against BCMAENGMAB SARL·Filed 2018·Granted Dec 1, 2020·1 cites·4 claims
- 2678US2021253703A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 2778US2021253704A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2021·Application pending·0 cites
- 2877US12139553B2T cell activating bispecific antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Granted Nov 12, 2024·0 cites·20 claims
- 2977US10882918B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2017·Granted Jan 5, 2021·1 cites·33 claims
- 3077US2021101979A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 3176US11013801B2Treatment methodHOFFMANN LA ROCHE·Filed 2016·Granted May 25, 2021·1 cites·28 claims
- 3276US2023372479A1Treatment methodHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3375US10766967B2Bispecific T cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Sep 8, 2020·1 cites·50 claims
- 3475US2020385470A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2020·Application pending·0 cites
- 3574US2023052521A1Treatment methodHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3673US2023322957A1Monoclonal antibodies against bcmaENGMAB SARL·Filed 2022·Application pending·0 cites
- 3772US2022169748A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 3871US2024109976A1Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonistsHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 3971US2022054635A1Treatment methodHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4070US2019177413A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2019·Application pending·0 cites
- 4169US2021252144A1Treatment methodHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4269US2021355234A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 4369US2018312589A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Application pending·0 cites
- 4469US2023355754A1Combination therapy of tumor targeted icos agonists with t-cell bispecific moleculesHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 4568US2021070873A1Method for the selection of antibodies against bcmaENGMAB SARL·Filed 2020·Application pending·0 cites
- 4667US2021101996A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4762US2020283545A1Monoclonal antibodies against bcmaENGMAB SARL·Filed 2020·Application pending·0 cites
- 4860US2020347147A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 4959US2021070882A1Bispecific t cell activating antigen binding moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 5057US2020306373A1Combination therapy of tumor targeted icos agonists with t-cell bispecific moleculesHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
Showing the top 50 of 66 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Marina Bacac files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →